Man Group plc Buys New Shares in Eton Pharmaceuticals, Inc. $ETON

Posted by Francis Steltz on Sep 4th, 2026

Man Group plc purchased a new position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON – Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 16,152 shares of the company’s stock, valued at approximately $585,000. Man Group plc owned 0.06% of Eton Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the company. Sei Investments Co. bought a new position in Eton Pharmaceuticals in the 1st quarter worth $1,432,000. Bank of Nova Scotia purchased a new position in shares of Eton Pharmaceuticals during the second quarter valued at about $623,000. EcoR1 Capital LLC increased its position in shares of Eton Pharmaceuticals by 7.0% during the first quarter. EcoR1 Capital LLC now owns 2,171,938 shares of the company’s stock valued at $53,603,000 after buying an additional 141,394 shares during the period. Bank of America Corp DE raised its stake in Eton Pharmaceuticals by 37.8% in the first quarter. Bank of America Corp DE now owns 144,367 shares of the company’s stock worth $3,563,000 after buying an additional 39,571 shares in the last quarter. Finally, Walleye Capital LLC purchased a new stake in Eton Pharmaceuticals in the first quarter worth about $2,023,000. Hedge funds and other institutional investors own 27.86% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ETON. Zacks Research raised Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, August 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Friday, July 17th. Craig Hallum raised their price objective on Eton Pharmaceuticals from $40.00 to $62.00 and gave the company a “buy” rating in a research report on Tuesday, July 28th. Canaccord Genuity Group boosted their target price on shares of Eton Pharmaceuticals from $60.00 to $68.00 and gave the company a “buy” rating in a report on Friday, August 14th. Finally, HC Wainwright upped their target price on shares of Eton Pharmaceuticals from $65.00 to $70.00 and gave the stock a “buy” rating in a research report on Friday, August 14th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $67.50.

Get Our Latest Report on Eton Pharmaceuticals

Insider Activity at Eton Pharmaceuticals

In other Eton Pharmaceuticals news, Director Paul V. Maier sold 50,000 shares of the firm’s stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $59.07, for a total transaction of $2,953,500.00. Following the completion of the sale, the director directly owned 59,745 shares in the company, valued at approximately $3,529,137.15. This trade represents a 45.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jennifer Mckie Adams sold 50,000 shares of Eton Pharmaceuticals stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $32.48, for a total transaction of $1,624,000.00. Following the completion of the transaction, the director directly owned 50,000 shares of the company’s stock, valued at $1,624,000. This trade represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 125,000 shares of company stock valued at $6,204,250. 16.49% of the stock is owned by insiders.

Eton Pharmaceuticals Stock Down 3.3%

ETON stock opened at $59.90 on Friday. The business has a 50 day moving average of $47.32 and a 200 day moving average of $33.27. The firm has a market cap of $1.71 billion, a PE ratio of 157.63 and a beta of 0.90. Eton Pharmaceuticals, Inc. has a twelve month low of $14.27 and a twelve month high of $66.37. The company has a quick ratio of 1.30, a current ratio of 1.52 and a debt-to-equity ratio of 0.41.

Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) last released its earnings results on Thursday, August 13th. The company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.19 by $0.24. Eton Pharmaceuticals had a return on equity of 40.13% and a net margin of 12.02%.The business had revenue of $37.59 million for the quarter, compared to the consensus estimate of $27.11 million. On average, research analysts forecast that Eton Pharmaceuticals, Inc. will post 1.13 EPS for the current fiscal year.

About Eton Pharmaceuticals

(Free Report)

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.